| Gene symbol | CCR5 | Synonyms | CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p21.31 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | C-C motif chemokine receptor 5 | ||||
| GTO ID | GTC0711 |
| Trial ID | ACTRN12615000763549 |
| Disease | Primary HIV-1 Infection |
| Altered gene | CCR5 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Cal-1 |
| Phase | Phase1|Phase2 |
| Recruitment status | Withdrawn |
| Title | An adaptive phase I/II, dose-ranging study to evaluate the safety and feasibility of busulfan conditioning prior to transplant of CD4+ T lymphocytes and CD34+ haematopoietic stem/progenitor cells (HSPCs) transduced with LVSH5/C46 (CAL-1), in adults diagnosed at primary HIV-1 infection who are established on effective combination antiretroviral therapy (ART) |
| Year | 2015 |
| Country | Australia|United States |
| Company sponsor | Calimmune Australia Pty Limited |
| Vector information | |||
|
|||
| Cohort 1 | |||||||
|
|||||||